SEARCH:   Advanced

Blood, 1 August 2007, Vol. 110, No. 3, pp. 827-832. Prepublished online as a Blood First Edition Paper on April 6, 2007April 30, 2007; DOI 10.1182/blood-2007-01-067728. This Article Full Text (PDF) All Versions of this Article: blood-2007-01-067728v1 blood-2007-01-067728v2 110/3/827    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Rhee, F. Articles by Barlogie, B. Search for Related Content PubMed PubMed Citation Articles by van Rhee, F. Articles by Barlogie, B. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 11, 2007 Accepted February 28, 2007 High serum free-light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D Shaughnessy Jr, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, and Bart Barlogie* Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR Cancer Research and Biostatistics, CRAB, Seattle, WA * Corresponding author; email: barlogiebart{at}uams.edu. Serum free-light chain (SFLC) levels are useful for diagnosing non-secretory myeloma and monitoring response in light-chain only disease, especially in the presence of renal failure. As part of a tandem autotransplant trial for newly diagnosed multiple myeloma, SFLC levels were measured at baseline, within 7 days of starting the first cycle and both prior to the second induction cycle and the first transplant. SFLC baseline levels >75mg/dL (top-tertile) identified 33% of 301 patients with higher near-complete response rate (n-CR) to induction therapy (37% v 20%, p=0.002) yet inferior 24-mo overall survival (OS: 76% v 91%, p<0.001) and event-free survival (EFS:73% v 90%, p<0.001), retaining independent prognostic significance for both EFS (HR=2.40, p=0.008) and OS (HR=2.43, p=0.016). Baseline SFLC >75mg/dL was associated with light-chain only secretion (p<.001), creatinine >=2mg/dL (p<.001), beta-2-microglobulin >=3.5mg/L (p<.001), lactate dehydrogenase >=190U/L (p<.001) and bone marrow plasmacytosis >30% (p=.003). Additional independent adverse implications were conferred by top-tertile SFLC reductions prior to cycle 2 (OS: HR=2.97, p=0.003; EFS: HR=2.56, p=0.003) and pre-transplant (OS: HR=3.31, p=0.001; EFS: HR=2.65, p=0.003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline -reflecting more aggressive disease- and steeper reductions after therapy identified patients with inferior survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness Frits van Rhee, John Crowley, and Bart Barlogie Blood 2008 111: 2491. [Full Text] [PDF] FMC7 is an epitope of CD20 Julie P. Deans and Maria J. Polyak Blood 2008 111: 2492. [Full Text] [PDF] This article has been cited by other articles: A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al. Appraisal of immunoglobulin free light chain as a marker of response Blood, May 15, 2008; 111(10): 4908 - 4915. [Abstract] [Full Text] [PDF] A. Dispenzieri Is early, deep free light chain response really an adverse prognostic factor? Blood, February 15, 2008; 111(4): 2490 - 2491. [Full Text] [PDF] F. van Rhee, J. Crowley, and B. Barlogie Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness Blood, February 15, 2008; 111(4): 2491 - 2491. [Full Text] [PDF] B. Barlogie, G. Tricot, J. Haessler, F. van Rhee, M. Cottler-Fox, E. Anaissie, J. Waldron, M. Pineda-Roman, R. Thertulien, M. Zangari, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989 Blood, January 1, 2008; 111(1): 94 - 100. [Abstract] [Full Text] [PDF] J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling Clin. Cancer Res., December 1, 2007; 13(23): 7073 - 7079. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020